{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:13:56Z","timestamp":1778944436661,"version":"3.51.4"},"reference-count":38,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004000","name":"Guangzhou Science and Technology Program Key Projects","doi-asserted-by":"publisher","award":["202002020074"],"award-info":[{"award-number":["202002020074"]}],"id":[{"id":"10.13039\/501100004000","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Guangdong Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2022A1515012582"],"award-info":[{"award-number":["2022A1515012582"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.cllc.2025.06.010","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T11:57:26Z","timestamp":1751025446000},"page":"e547-e559.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of First-Line Anti-PD-1 Antibody Combined With Taxane-Platinum Versus Taxane-Platinum Alone in Metastatic Thymic Carcinoma: A Real-World Retrospective Study"],"prefix":"10.1016","volume":"26","author":[{"given":"Maolin","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaqi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuhui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dilimulati","family":"Abulizi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yajing","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.cllc.2025.06.010_bib0001","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1016\/j.ejca.2011.08.008","article-title":"Rare cancers are not so rare: the rare cancer burden in europe","volume":"47","author":"Gatta","year":"2011","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.cllc.2025.06.010_bib0002","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1002\/cncr.34678","article-title":"Understanding the landscape of immunotherapy in thymic epithelial tumors","volume":"129","author":"Maniar","year":"2023","journal-title":"Cancer"},{"issue":"167","key":"10.1016\/j.cllc.2025.06.010_bib0003","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0174-2022","article-title":"ERN-LUNG Core Network mesothelioma. Rare thoracic cancers: a comprehensive overview of diagnosis and management of small cell lung cancer, malignant pleural mesothelioma and thymic epithelial tumours","volume":"32","author":"Dumoulin","year":"2023","journal-title":"Eur Respir Rev"},{"issue":"2","key":"10.1016\/j.cllc.2025.06.010_bib0004","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jtho.2021.10.010","article-title":"The 2021 WHO classification of tumors of the thymus and mediastinum: what is new in thymic epithelial, germ cell, and mesenchymal tumors?","volume":"17","author":"Marx","year":"2022","journal-title":"J Thorac Oncol"},{"issue":"12","key":"10.1016\/j.cllc.2025.06.010_bib0005","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1097\/JTO.0000000000000363","article-title":"Clinical characteristics and outcomes for patients with thymic carcinoma: evaluation of masaoka staging","volume":"9","author":"Litvak","year":"2014","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2025.06.010_bib0006","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jtcvs.2014.09.124","article-title":"Thymic carcinoma outcomes and prognosis: results of an international analysis","volume":"149","author":"Ahmad","year":"2015","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"4","key":"10.1016\/j.cllc.2025.06.010_bib0007","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ejcts\/ezv239","article-title":"Long-term outcome and prognostic factors of surgically treated thymic carcinoma: results of 306 cases from a japanese nationwide database study","volume":"49","author":"Hishida","year":"2016","journal-title":"Eur J Cardiothorac Surg"},{"issue":"11","key":"10.1016\/j.cllc.2025.06.010_bib0008","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.jtho.2022.08.007","article-title":"Surgical, radiation, and systemic treatments of patients with thymic epithelial tumors: a clinical practice guideline","volume":"17","author":"Falkson","year":"2022","journal-title":"J Thorac Oncol"},{"issue":"5","key":"10.1016\/j.cllc.2025.06.010_bib0009","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.jtho.2022.01.021","article-title":"Thymic carcinomas-a concise multidisciplinary update on recent developments from the thymic carcinoma working group of the international thymic malignancy interest group","volume":"17","author":"Roden","year":"2022","journal-title":"J Thorac Oncol"},{"issue":"10278","key":"10.1016\/j.cllc.2025.06.010_bib0010","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/S0140-6736(20)32598-8","article-title":"Enhancing anti-tumour efficacy with immunotherapy combinations","volume":"397","author":"Meric-Bernstam","year":"2021","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.cllc.2025.06.010_bib0011","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1200\/JCO.2017.77.3184","article-title":"Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial","volume":"37","author":"Cho","year":"2019","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.cllc.2025.06.010_bib0012","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study","volume":"19","author":"Giaccone","year":"2018","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.cllc.2025.06.010_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101576","article-title":"Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial","volume":"8","author":"Girard","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.cllc.2025.06.010_bib0014","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2019.03.012","article-title":"Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study","volume":"113","author":"Katsuya","year":"2019","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.cllc.2025.06.010_bib0015","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jtho.2020.11.003","article-title":"Durable response in patients with thymic carcinoma treated with pembrolizumab after prolonged follow-up","volume":"16","author":"Giaccone","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2025.06.010_bib0016","series-title":"NCCN Clinical Practice Guidelines in Oncology: Thymomas and Thymic Carcinomas Version 2","year":"2022"},{"issue":"3","key":"10.1016\/j.cllc.2025.06.010_bib0017","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrclinonc.2015.209","article-title":"Combination cancer immunotherapies tailored to the tumour microenvironment","volume":"13","author":"Smyth","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"10.1016\/j.cllc.2025.06.010_bib0018","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/ijc.34948","article-title":"Chemotherapy versus chemotherapy plus immune checkpoint inhibitors for the first-line treatment of unresectable thymic carcinoma: a multicenter retrospective study","volume":"155","author":"Zhang","year":"2024","journal-title":"Intl Journal of Cancer"},{"key":"10.1016\/j.cllc.2025.06.010_bib0019","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2022.06.059","article-title":"Treatment outcomes and prognosis of immune checkpoint inhibitors therapy in patients with advanced thymic carcinoma: a multicentre retrospective study","volume":"174","author":"Wang","year":"2022","journal-title":"European Journal of Cancer"},{"issue":"2","key":"10.1016\/j.cllc.2025.06.010_bib0020","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"European Journal of Cancer"},{"issue":"1","key":"10.1016\/j.cllc.2025.06.010_bib0021","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12876-022-02199-9","volume":"22","author":"Ding","year":"2022","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.cllc.2025.06.010_bib0022","unstructured":"Common terminology criteria for adverse events (CTCAE). Accessed: February 25, 2025. Available at: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_archive."},{"issue":"6","key":"10.1016\/j.cllc.2025.06.010_bib0023","doi-asserted-by":"crossref","first-page":"bbae547","DOI":"10.1093\/bib\/bbae547","article-title":"Optimized patient-specific immune checkpoint inhibitor therapies for cancer treatment based on tumor immune microenvironment modeling","volume":"25","author":"Yao","year":"2024","journal-title":"Brief Bioinform"},{"issue":"12","key":"10.1016\/j.cllc.2025.06.010_bib0024","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","article-title":"Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors","volume":"17","author":"Galluzzi","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/j.cllc.2025.06.010_bib0025","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/annonc\/mdy551","article-title":"Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors","volume":"30","author":"Heinhuis","year":"2019","journal-title":"Ann Oncol"},{"issue":"15","key":"10.1016\/j.cllc.2025.06.010_bib0026","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1200\/JCO.2010.32.9607","article-title":"Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma","volume":"29","author":"Lemma","year":"2011","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.cllc.2025.06.010_bib0027","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/j.jtho.2021.07.004","article-title":"The international thymic malignancy interest group classification of thymoma recurrence: survival analysis and perspectives","volume":"16","author":"Chiappetta","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"3","key":"10.1016\/j.cllc.2025.06.010_bib0028","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S1470-2045(25)00001-4","article-title":"Activity and safety of atezolizumab plus carboplatin and paclitaxel in patients with advanced or recurrent thymic carcinoma (MARBLE): a multicentre, single-arm, phase 2 trial","volume":"26","author":"Shukuya","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2025.06.010_bib0029","series-title":"A Phase II Study of Tislelizumab Combined with Chemotherapy in Patients with Thymic Carcinoma [Abstract]. 2024 World Conference on Lung Cancer (WCLC)","author":"Wu","year":"2024"},{"issue":"9","key":"10.1016\/j.cllc.2025.06.010_bib0030","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.annonc.2024.06.002","article-title":"Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671)","volume":"35","author":"Proto","year":"2024","journal-title":"Annals of Oncology"},{"issue":"12","key":"10.1016\/j.cllc.2025.06.010_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtocrr.2024.100738","article-title":"S1701, A randomized phase 2 trial of carboplatin-Paclitaxel with and without Ramucirumab in patients with locally advanced, recurrent, or metastatic thymic carcinoma","volume":"5","author":"Tsao","year":"2024","journal-title":"JTO Clinical and Research Reports"},{"issue":"8","key":"10.1016\/j.cllc.2025.06.010_bib0032","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1001\/jamaoncol.2022.1981","article-title":"Association of high tumor mutation burden in non-small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 expression levels","volume":"8","author":"Ricciuti","year":"2022","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.cllc.2025.06.010_bib0033","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1111\/cas.14409","article-title":"CD20+ tumor-infiltrating immune cells and CD204+ M2 macrophages are associated with prognosis in thymic carcinoma","volume":"111","author":"Sato","year":"2020","journal-title":"Cancer Sci"},{"issue":"9","key":"10.1016\/j.cllc.2025.06.010_bib0034","article-title":"Molecular predictors of response to pembrolizumab in thymic carcinoma","volume":"2","author":"He","year":"2021","journal-title":"Cell Rep Med"},{"issue":"1","key":"10.1016\/j.cllc.2025.06.010_bib0035","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12943-023-01772-4","article-title":"Immunotherapy of thymic epithelial tumors: molecular understandings and clinical perspectives","volume":"22","author":"Ao","year":"2023","journal-title":"Mol Cancer"},{"key":"10.1016\/j.cllc.2025.06.010_bib0036","doi-asserted-by":"crossref","DOI":"10.1007\/s10637-024-01497-1","article-title":"Immunotherapy in thymic epithelial tumors: an attractive dilemma","author":"Damaj","year":"2025","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.cllc.2025.06.010_bib0037","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.3389\/fimmu.2020.01088","article-title":"Looking for the optimal PD-1\/PD-L1 inhibitor in cancer treatment: a comparison in basic structure, function, and clinical practice","volume":"11","author":"Chen","year":"2020","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.cllc.2025.06.010_bib0038","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1007\/s00262-022-03140-5","article-title":"Severe immune-related adverse events of immune checkpoint inhibitors for advanced non-small cell lung cancer: a network meta-analysis of randomized clinical trials","volume":"71","author":"Gu","year":"2022","journal-title":"Cancer Immunol Immunother"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730425001445?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730425001445?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:03:00Z","timestamp":1778943780000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730425001445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1525730425001445"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2025.06.010","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of First-Line Anti-PD-1 Antibody Combined With Taxane-Platinum Versus Taxane-Platinum Alone in Metastatic Thymic Carcinoma: A Real-World Retrospective Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2025.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}